

**Cell & Gene Therapy
Bioprocessing &
Commercialization**

VIRTUAL
19 - 22 October 2020

**Cell Therapy
Manufacturing &
Gene Therapy Congress**

THE CELL AND GENE THERAPY CONFERENCE FOR GROUND BREAKING BIOPROCESSING, MANUFACTURING & SUPPLY CHAIN STRATEGIES

World renowned leaders share the latest analytical techniques & vector technologies to revolutionize your cell, gene & gene edited ex vivo cell therapy programs

HEAR FROM THE BRIGHTEST MINDS IN CELL AND GENE THERAPY



Kai Pinkernell

Chief Medical Officer (CMO) and Chief Development Officer (CDO), Medigene, Germany




Philippe Parone

Director, Industrialization, Celyad



Kathryn Corzo

Head of Development Oncology Cell Therapies, Takeda Oncology



Jennifer Adrian

Manager, Cellular Therapy Manufacturing Operations, bluebird bio, USA



Mike Fraser

General Manager of EMEA, AveXis Inc



Devyn Smith

COO, Sigilon Therapeutics



Betsy Rezner

Director, Process & Assay Development at Fate Therapeutics Inc.



Dominic Schmidt

Partner, Syncona



Brought to you by
informaconnect

Event Partner:  Biotech

www.CellGeneEvent.com

Expert industry speakers. Hundreds of connections. Unparalleled networking opportunities. **All delivered ONLINE, direct to you**



EXPERT INSIGHT DIRECT TO YOUR OWN SCREEN

Watch live or catch-up on demand.

Our platform enables you to watch sessions live and interact with the speakers, panels, and Q&As in real-time as if you were in the room with them.

Simply log onto the digital platform, browse the agenda and tune into the sessions that interest you the most.

Plus, content will be available on demand so you can catch up on anything you might have missed at your leisure.



VIRTUAL NETWORKING

Our virtual platform will enable face-to-face connections via video chat, ensuring you can meet the people that matter most to you.

Create your personal profile to indicate who you are, what you're looking for and who you want to meet. You can filter fellow attendees to find the people most relevant to you and reach out to arrange a video chat. You can even invite other attendees to join the meeting in real time - so if you want to bring your product experts or sales representatives at a crucial moment, they can join the conversation instantly.

Our networking platform will make it easy to connect with the right people - helping you to have the conversations that matter with the people who matter to you..

“

“I am glad to see that Informa Connect is paving the way to run Cell Therapy Bioprocessing & Commercialization and Cell & Gene Therapy Manufacturing Europe as a Virtual Conference and Exhibition during the Covid19 pandemic. It is particularly important since cell therapies are in the forefront of Covid19 tested treatments.”

Lior Raviv, Vice President Development & Operations, Pluristem Therapeutics

”

WATCH LIVE SESSIONS: Keynotes, Q&A's, Discussions: October 19 - 22

Monday 19th October

	Exhibition Viewing Time & Live Discussion Groups			
	Cell Therapy	Ex Vivo Cell Therapy	Gene Therapy	Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
7:30	Data Governance and Data Integrity as a framework during Process Development Sara Levy, CSV & Data integrity Manager, Pluristem Therapeutics Inc., <i>Israel</i>	Senti Bio Case Study – Gene Edited MSC Philip Lee, COO and Co-Founder, Senti Biosciences, <i>USA</i>	Next Generation Cell Line Development & Large-Scale Bioprocessing Technology Sam Wadsworth, Chief Scientific Officer, Ultragenyx Gene Therapy, <i>USA</i>	Scalable, Consistent, Cost-effective Manufacturing for Tissues and Organs Mary Clare McCorry Director, Technology and Process Development, ARMI BioFabUSA
7:50	Speaker Q&A - Cell Therapy Process Development <i>Moderator:</i> Lior Raviv, Vice President Development & Operations, Pluristem Therapeutics Inc., <i>Israel</i> <i>Speakers:</i> Sara Levy, CSV & Data integrity Manager, Pluristem Therapeutics Inc. Mustafa Munye, Lead Scientist, Cell and Gene Therapy Catapult Rachel Yost, Senior Process Engineer, Juno Therapeutics Inc.	Speaker Q&A - Auto vs. Allo Manufacturing & Infrastructure <i>Moderator:</i> Geoffrey Hodge, formerly, Chief Technical Officer, Unum Therapeutics Inc., <i>USA</i> <i>Speakers:</i> Philip Lee, COO and Co-Founder, Senti Biosciences, <i>USA</i> Gregory Russotti, Chief Technology Officer, Century Therapeutics, LLC, <i>USA</i>	Speaker Q&A Sam Wadsworth, Chief Scientific Officer, Ultragenyx Gene Therapy	The Importance of High Quality Raw Materials for Developing your Cell or Gene-Modified Cell Therapy: A Master Cell Bank Case Study Ben Fryer, Co-Founder, Pluristyx
8:15	Coffee Break and Exhibition Viewing Time			
	Live Plenary Session			
9:00	Opening Remarks from the Chairperson Miguel Forte, CEO, Bone Therapeutics, <i>Belgium</i>			
9:10	PANEL: COVID-19: Trailblazers in the CGT Industry <div>Chris Gemmiti, Vice President, Operations, Sentien Biotechnologies, Inc. Lawrence C. Thompson, Senior Principal Scientist, Pfizer Inc., <i>USA</i> Claudia Berron, Senior Vice President, Business Development and Commercial Operations – Biopharma Production, Avantor, <i>USA</i> Camillo Ricordi, MD, FNAI, Stacy Joy Goodman Professor of Surgery and Chief, Division of Cellular Transplantation, Distinguished Professor of Medicine, Professor of Biomedical Engineering, Microbiology and Immunology, Director, Diabetes Research Institute and Cell Transplant Center, University of Miami, Fellow, National Academy of Inventors, <i>USA</i>, Member, Italian Supreme Council of Health</div> <div>Racheli Ofir, Vice President Research & Intellectual Property, Pluristem Therapeutics Inc. John Lewis, Ph.D. - Co-founder and CEO, Aegis Life Inc., <i>USA</i> and Entos Pharmaceuticals, <i>CA</i></div>			
10:00	PANEL: Investment in the CGT space: trends, technologies and early stage success <div>Jak Knowles, VP Venture Investments, Bayer Joey Mason, Vice President, M Ventures</div> <div>Mike Zhao, Senior Vice President, MSQ Ventures, <i>USA</i> Dominic Schmidt, Partner, Syncona, <i>UK</i></div>			
11:00	Sponsor Presentation			
	Exhibition Viewing Time & Live Discussion Groups			
11:30	Risk-Based Approaches for Autologous CAR T-Cell Therapy Comparability Erica Bust, Sr. Process Engineer, Juno Therapeutics, a Bristol Myers Squibb Company, <i>USA</i>	Encapsulation Approaches – A Case study from Sigilon Martha Rook, SVP, Manufacturing, Sigilon Therapeutics Inc., <i>USA</i>	Assessing the Future Prospects of Upstream Bioprocessing Systems for Commercial AAV Production Scott Jeffers, Director, UniQure, <i>USA</i>	Optimization of Cell Culture and Differentiation Jan Jensen, CEO and Founder, Trailhead Biosystems
11:50	Speaker Q&A - Process Development Considerations & Strategies <i>Moderator:</i> Jon Rowley, Founder & Chief Product Officer, RoosterBio, Inc., <i>USA</i> <i>Speakers:</i> Margarida Serra, Head of Stem Cell Bioengineering Lab, iBET - Instituto de Biologia Experimental e Tecnológica. Erica Bust, Sr. Process Engineer, Juno Therapeutics, a Bristol Myers Squibb Company, <i>USA</i>	Speaker Q&A - Auto vs. Allo Manufacturing & Infrastructure <i>Moderator:</i> Ali Mohamed, VP CMC, Immatics, <i>USA</i> <i>Speakers:</i> Shyam Patel, Director Business Development, California Institute for Regenerative Medicine, <i>USA</i> Martha Rook, SVP, Manufacturing, Sigilon Therapeutics Inc., <i>USA</i> Vadim Klyushnichenko, VP Pharmaceutical Development and Quality, Calibr at Scripps Research, <i>USA</i>	Speaker Q&A - High Throughput Applications in Production Platforms & Enabling Manufacturing Tech <i>Speakers:</i> Scott Jeffers, Director, UniQure, <i>USA</i> Sha Sha, Postdoc, Massachusetts Institute of Technology, <i>USA</i>	Unique Methods for Cell Harvest Sonia Bulsara, Application Specialist Manager, US & Canada, Cell and Gene Therapy, Cytiva
12:15	Networking Reception			

Tuesday 20th October

	Cell Therapy	Ex Vivo Cell Therapy	Gene Therapy	Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
8:00	Exhibition Viewing Time & Networking Breakfast			
	Live Plenary Session			
9:00	Opening Remarks from the Chairperson			
9:10	Fate Therapeutic’s Off-the-shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy Programs Betsy Rezner, Senior Director, Process & Assay Development, Fate Therapeutics Inc., USA			
9:30	Scalable Manufacture Platform of Human iPS-NK Cells for Off-the-Shelf Cell Therapies Allen Feng, Chief Scientific Officer, HebeCell Corp, USA			
9:50	Non- Gene edited Allogeneic cells Philippe Parone, Director, Industrialization, Celyad, Belgium			
10:10	The Potential of CAR-NK Kathryn Corzo, Head of Development Oncology Cell Therapies, Takeda Oncology			
10:30	Sponsored Presentation			
11:00	Starting Material Standardization Christiane Niederlaender, Director, AMBR Consulting Ltd, formerly MHRA, UK	Efficiency Challenges as a Result of Viral Vectors Adam Haskett, Associate Director, External Manufacturing, Kite Pharma, USA		Scaffold Fabrication Michael Francis, Chief Science Officer & Founder, Embody, Faculty at EVMS
11:20	Speaker Q&A - Raw Material, Viral Vector & Supply Chain Considerations Moderator: Christopher Bravery, Principal Consultant, Consulting on Advanced Biologicals, UK Speakers: Christiane Niederlaender, Director, AMBR Consulting Ltd, formerly MHRA, UK Scott R. Burger, Principal, Advanced Cell & Gene Therapy, LLC, USA Tom Walls, Associate Director Supply Chain, bluebird bio, USA			Essential to Biological Relevance and Translational Potential: Standardized, Well-Characterized GMP-grade Tissue-Specific Extracellular Matrix (ECM) Components for Scaffold Fabrication John O’Neill, Co-Founder & Chief Scientific Officer, Xylyx Bio, Inc.
11:45	End of Day			

WATCH LIVE SESSIONS: Keynotes, Q&A's, Discussions: October 19 - 22

Wednesday 21st October

	Cell Therapy	Ex Vivo Cell Therapy	Gene Therapy	Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
7:30	Analytical Method Development and Validation – Building the Characterization Testing Foundation & Toolkit Lara Ionescu Silverman, Senior Director, Research and Development, DiscGenics, USA		The Case for rAAV Titration by HPLC Franz Schnetzinger, Director Analytical Development, Gyroscope Therapeutics	Developing Your Manufacturing Process from A->Z Priya Baraniak, Vice President, Corporate Development, Organobio
7:50	Speaker Q&A - Cell Therapy Analytics – Testing, Characterization & Validation Strategies <i>Moderator:</i> Barrett J. Nehila, Associate Director, Analytical Development, Torque Therapeutics <i>Speakers:</i> Steve Oh, Director of the Stem Cell Bioprocessing, A*STAR, Bioprocessing Technology Institute, Singapore Lara Ionescu Silverman, Senior Director, Research and Development, DiscGenics, USA		Speaker Q&A - Gene Therapy Upstream & Downstream Considerations Thomas R. Kreil, VP, Global Head Pathogen Safety, Takeda Inc., Austria	Speaker Q&A
8:15	Coffee & Exhibition Viewing Time			
	Live Plenary Session			
9:00	Opening Remarks from the Chairperson Anthony Davies, Founder & CEO, Dark Horse Consulting, USA			
9:10	State of the Industry Janet Lynch Lambert, Chief Executive Office, Alliance for Regenerative Medicine, USA			
9:45	DUAL DIALOGUE: Creating a Partnership in Advanced Therapies to Enable Seamless Transition of a Program Janelle A. Sabo, PharmD, RPh, MBA, Global Head, Clinical Supplies, Systems and Innovation, Eli Lilly Research and Development Devyn Smith, COO, Sigilon Therapeutics			
10:20	PANEL: Reimbursement Models for Novel Therapies <i>Moderator:</i> Kevin Mayo, Managing Partner, Venture Genome Phillip D. Carter, Head, U.S. Market Access, Orchard Therapeutics Mike Fraser, General Manager of EMEA, AveXis Inc., Switzerland			
11:00	Sponsor Presentation			
11:30	Augmenting Automated Analytics for Cell & Gene Therapy Manufacture Veeren Chauhan, Nottingham Research Fellow, Bio-inspired Therapeutics, University of Nottingham, USA	Cryopreservation & Storage of Viral Vectors Erik J. Woods, Co-Founder, EVP of Technical Operations & Chief Science Officer, Ossium Health, Inc, USA	Emerging upstream bioprocessing and analytical tools for vector manufacture Michael J. DiBiasio-White, Sr. Scientist: BioProcess Development/Protein Sciences, Ring Therapeutics, USA	Development of Modular Biofabrication Platforms for Diverse Tissue Engineering Applications George Christ, Professor of Biomedical Engineering and Orthopaedic Surgery, University of Virginia
11:50	Speaker Q&A - Cell Therapy Analytics – Testing, Characterization & Validation Strategies <i>Speakers:</i> Michael Roberts, Chief Technology Officer (Europe), Asklepios BioPharmaceutical, Inc., UK Qin Zou, Associate Research Fellow, Pfizer Analytics Jennifer L. Dashnau, Head of Analytical Development and Quality Control, Century Therapeutics	Speaker Q&A - Cryopreservation & Vein-to-vein Considerations <i>Moderator:</i> Donald Singer, Consultant, formerly GSK Senior Fellow, USA <i>Speakers:</i> Erik J. Woods, Co-Founder, EVP of Technical Operations & Chief Science Officer, Ossium Health, Inc, USA Jason Acker, Professor, Laboratory Medicine and Pathology, University of Alberta, Canada David McKenna, Professor and American Red Cross Chair in Transfusion Medicine, Department of Laboratory Medicine and Pathology, University of Minnesota, USA	Speaker Q&A - Gene Therapy Analytics <i>Moderator:</i> Franz Schnetzinger, Director Quality Control & CMC Analytical Development, Gyroscope Therapeutics Limited, UK <i>Speakers:</i> David Dobnik, Senior Research Associate, National Institute of Biology, Slovenia Michael J. DiBiasio-White, Sr. Scientist: BioProcess Development/Protein Sciences, Ring Therapeutics, USA	Novel Bioreactor System for Fabrication of Musculoskeletal Tissues Lisa Larkin, Ph.D., Professor Molecular & Integrative Physiology Biomedical Engineering, University of Michigan, USA
12:15	End of Day			

Thursday 22nd October

	Cell Therapy	Ex Vivo Cell Therapy	Gene Therapy	Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
8:00	Process Control strategies for Cell Therapy Rachel Yost, Senior Process Engineer, Juno Therapeutics Inc., USA	Delivering on the Promise of Producing Cost-Effective, High-Quality Allogeneic Immune Cell Therapies Gregory Russotti, Chief Technology Officer, Century Therapeutics, LLC, USA	Optimizing Viral Vector Production Nicole Nunez, Process Development Scientist, Eureka Therapeutics, USA	Microscale Sensors and Systems for Tissue Engineering and Organs on a Chip Applications Mehmet Dokmeci, Adjunct Professor, University of California (UCLA)
8:20	Sponsor Presentation	Sponsor Presentation	Sponsor Presentation	Robust Preclinical Oxygen Imager JIVA-25 for Cancer and Regenerative Medicine Therapy Development Mrignayani Kotecha, Co-Founder, CEO, O2M Technologies
8:50	Coffee & Exhibition Viewing Time			
	Live Plenary Session			
9:20	Opening Remarks from the Chairperson Nick Timmins, VP of Cell Technologies, Artisan Biotechnologies, Canada			
9:30	PANEL: Strategies and Challenges in Manufacturing and Commercialization Moderator: Thomas Bollenbach, CTO, Advanced Regenerative Manufacturing Institute Panelists: Mahendra Rao, CEO, panCELLa Inc Chris Gemmiti, VP Operations, Sentien Biotechnologies, Inc., USA Kai Pinkernell, Chief Medical Officer (CMO) and Chief Development Officer (CDO), Medigene, Germany Ger Brophy, Executive Vice President, Biopharma Production, Avantor, USA			
10:10	PANEL: Autologous Manufacturing – What will Autologous Manufacturing of the Future Look Like? Panelists: Jennifer Adrian, Manager, Cellular Therapy Manufacturing Operations, bluebird bio, USA Adam Haskett, Associate Director, External Manufacturing, Kite Pharma, USA			
10:50	Sponsor Presentation			
11:20	Sponsor Presentation			

ON-DEMAND PRESENTATIONS

These ON-DEMAND presentations will be available to view 24 hours a day starting October 12 for 30 Days

We Encourage You to View as Many of these On-Demand Presentations at Possible Prior to the “Live Event” Dates of October 19 - 22, so that you can fully participate in the live keynote Q&A, speaker panel discussions and other live topic networking activities....see WATCH LIVE schedule showing all the live activities you can participate in on October 19 - 22

Cell Therapy – Process Development Considerations & Strategies

Adherent Cell Manufacturing & Process Development

Lior Raviv, Vice President, Pluristem Therapeutics Inc.

Process Development Considerations for Exosomes

Jon A. Rowley, Ph.D., Founder & Chief Product Officer, RoosterBio Inc.

Closed, automated and controlled upstream processing for iPSC-derived cell therapies

Mustafa Munye, Lead Scientist, Cell and Gene Therapy Catapult

Adherent Cell Manufacturing & Process Development

Margarida Serra, Head of Stem Cell Bioengineering Lab, iBET - Instituto de Biologia Experimental e Tecnológica

Auto vs. Allo Manufacturing & Infrastructure

Will Allogeneic Cell Therapies Replace the Current Autologous Models?

Geoffrey Hodge, formerly Chief Technical Officer, Unum Therapeutics

Implementation of “off the shelf” Closed Systems fit for every purpose

Ali Mohamed, VP, CMC, Immatics

Development of modern biologics and cell therapy products through global CMOs

Vadim Klyushnichenko, VP Pharmaceutical Development and Quality, Calibr at Scripps Research

Feedback from the Industry Alliance Partnership (IAP) & CIRM Partnership and Commercialization Opportunities

Shyam Patel, Director Business Development, California Institute for Regenerative Medicine

High Throughput Applications & Production Platforms & Enabling Manufacturing Tech

Pathogen Safety Margins for Gene Therapy Manufacturing

Thomas Kreil, Vice President, Global Pathogen Safety, Takeda

Mechanistic Understanding of Recombinant Adeno – Associated Virus Production

Sha Sha, Postdoc, Massachusetts Institute of Technology

Exposing the Content of Different AAV Fractions after Ultracentrifugation

David Dobnik, Senior Research Associate, National Institute of Biology, Slovenia

Cell Therapy Analytics – Testing, Characterization & Validation Strategies

Quantitative Analytical Technologies for Cell & Gene Therapies

Barrett J. Nehila, Associate Director, Analytical Development, Torque Therapeutics

Manufacturing and quality control of cell therapies

Steve Oh, Director Stem Cell Bioprocessing & Institute Professor, Bioprocessing Technology Institute

AI in Cell and Gene Therapy Manufacturing

Michael Roberts, Chief Technology Officer (Europe), Asklepios BioPharmaceutical, Inc.

Holistic Characterization of AAV Capsid Particle Using Advanced Analytical Tools

Qin Zou, Ph.D., Senior Principal Scientist, Pfizer

Raw Materials Selection, Supply & Downstream Considerations

Starting Material Standardization for Auto and Allo Cell Therapies

Scott Burger, Principal, Advanced Cell & Gene Therapy

Sourcing Appropriate Starting and Ancillary Materials for Manufacturing Cell and Gene Therapy Products

Kathy Williams, VP of Quality and Reg Affairs, RoosterBio, Inc.

Raw Materials: BOMs, Risks & Securing Supply

Tom Walls, Associate Director Supply Chain, bluebirdbio

Fresh vs. Cryopreserved: Tightening up Supply Chains

Jason Acker, Professor, Laboratory Medicine and Pathology, University of Alberta

Phase Appropriate Thinking – Microbiology and Contamination Control

Donald Singer, Consultant, formerly, GSK Senior Fellow, Microbiology, Biopharmaceutical GMP Operations, USA

Product Dependent Cryopreservation Protocols

David McKenna, Professor and American Red Cross Chair in Transfusion Medicine, Department of Laboratory Medicine and Pathology

Cell and Gene Therapy Connect – Partnering Track

PANEL DISCUSSION: Partnering and Collaborations among Investors, Incubators and Biotechnology Companies

Jennifer Griffin, VP Industrial Strategy & Investments, Massachusetts Life Science Center
Paul Lammers, President & CEO, Triumvira Immunologics

PANEL DISCUSSION: Partnering Solutions for Staffing and Recruitment Issues in the CGT Space

Andrew Rigoglioso, Associate Director, Talent Acquisition, Cell Therapy Development & Operations, Bristol Myers Squibb
Alison Quelch, Director, Talent Acquisition, Global Product Development & Supply, Bristol-Myers Squibb
Jennifer Royal-Fitch, Lead Recruiter, Gene Therapy Program & The Orphan Disease Center, University of Pennsylvania

PANEL DISCUSSION: Bridging the Gap between Academia and Commercialization: When to Spin Out?

Elizabeth Schwarzbach, CBO, New York Stem Cell Foundation
Sofia Braag, Business Development Principal, University of Massachusetts Medical School
Carlton Anderson, COO, Ambulero

WATCH ON-DEMAND: SPOTLIGHT PRESENTATIONS

These ON-DEMAND presentations will be available to view 24 hours a day starting October 12 for 30 Days

We Encourage You to View as Many of these On-Demand Presentations at Possible Prior to the “Live Event” Dates of October 19 - 22, so that you can fully participate in the live keynote Q&A, speaker panel discussions and other live topic networking activities.... see WATCH LIVE schedule showing all the live activities you can participate in on October 19 - 22



Benchtop to Bioreactor: T-cell Culture and Expansion in Chemically Defined Media

Supriya Pokkali, Sr. Scientist II, Research and Development Department, FUJIFILM Irvine Scientific, R&D (Cell & Gene Therapy), USA



How to Commercially Scale T-cell Allogeneic Therapies

Jesse Trekker, Business Manager, Catalent Cell and Gene Therapy, Belgium



Closed Systems – The Solution for the Worlds Increasing Demands on CGT

Jayanthi Grebin, Senior Business Development Manager CGT, CPC - Colder Products Company, USA

SPONSORS:

Event Partners:  PALL Biotech



Conference Sponsors:  aldevron



Exhibitors:



CONTACT US TODAY TO BUILD YOUR CUSTOM SPONSORSHIP PACKAGE

Kristin Skahan (Companies A-L): +1.857.504.6730 | Kristin.Skahan@informa.com

Perri Lucatello (Companies M-Z): +44 (0) 20 7017 7247 | Perri.lucatello@informa.com

3 WAYS TO REGISTER



EASIEST:
www.CellGeneEvent.com



CALL
888-670-8200 or
+1.941.554.3500



EMAIL
register@informaconnect.com

RATES	Standard Rate
INDUSTRY Full conference pass	\$1,199
ACAD/GOVT Full conference pass	\$399
Acad/Govt poster presentation fee	FREE
Virtual Exhibit Hall Visitor	FREE

*Must select Poster Presentation during registration process, and must submit a poster abstract for approval by Friday, September 4th, 2020.

**Academic/Government rates are only extended to full-time employees of government, universities and university-affiliated hospitals with no industry affiliation.



PRESENT A VIRTUAL POSTER TO SHOWCASE YOUR LATEST RESEARCH

Highlight your organization's exciting research by presenting a scientific poster, which will be displayed in the virtual poster hall. You must be a registered attendee to present a poster. These features will be available to you as a virtual poster presenter:

- Dedicated Virtual Room for Your Poster
- Ability to Post a PDF of Your Poster for Virtual Attendees to View
- Ability to Post a Pre-Taped Audio or Video Introduction of Your Poster
- Dedicated Poster Viewing Times Which Allow Attendees to Visit You in Your Virtual Poster Room to Discuss Your Poster in Real-Time
- Ability to Have Face to Face (Shared Video) Virtual Meetings with Attendees Who Visit Your Poster Room

The deadline to submit your poster is: Friday 2nd October 2020.

Go to: <https://get.informaconnect.com/cell-therapy-bioprocessing/2020-poster/>